Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 10,428 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Cincinnati, Ohio Clear all
Active, not recruiting Phase 3 Interventional

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neurotoxicity
Interventions
temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

NCT00814255
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
17
States / cities
Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
12 Years and older
Enrollment
1,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 25, 2026, 8:20 AM EDT
Not listed Not applicable Interventional

Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain

NCT00087815
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Radiation Toxicity
Interventions
dexamethasone, hyperbaric oxygen, cognitive assessment, magnetic resonance imaging, positron emission tomography, quality-of-life assessment
Drug · Procedure
Lead sponsor
Barrett Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Evaluate the Hypoglossal Nerve Stimulator in Adolescents With Down Syndrome and Obstructive Sleep Apnea

NCT02344108
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Down Syndrome
Interventions
Inspire® Upper Airway Simulation System (Model 3028 IPG )
Device
Lead sponsor
Christopher Hartnick, M.D.
Other
Eligibility
10 Years to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

NCT02793817
View directory record Official record
Conditions
Post Surgical Ocular Inflammation and Pain
Interventions
KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Results available

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

NCT03497689
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Fresno, California • Torrance, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Results available

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

NCT01430403
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS), Placebo omalizumab, Placebo fluticasone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 3 Interventional

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677569
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 25, 2026, 8:20 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

NCT04334941
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
561
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 3 Interventional

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00259922
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
Placebo, Alvimopan, Alviompan
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
119
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Jul 25, 2026, 8:20 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee

NCT02847702
View directory record Official record
Conditions
Osteoarthritis Pain of the Knee
Interventions
VM902A 200-mg Capsules, VM902A 400-mg Capsules, Naproxen 500-mg Capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
31
States / cities
Birmingham, Alabama • Huntsville, Alabama • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00274924
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
104
States / cities
Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

NCT02101788
View directory record Official record
Conditions
Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions
Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Topotecan, Trametinib Dimethyl Sulfoxide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
488
States / cities
Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jul 25, 2026, 8:20 AM EDT
Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 25, 2026, 8:20 AM EDT
Completed No phase listed Observational

Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV

NCT01310205
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SCV-07
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Anaheim, California • Louisville, Kentucky • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Retrospective Independent Safety Review of Closed Irrisept Study

NCT05359666
View directory record Official record
Conditions
Adverse Events
Interventions
Irrisept, Standard of Care
Device
Lead sponsor
Irrimax Corporation
Industry
Eligibility
Not listed
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects

NCT02696902
View directory record Official record
Conditions
Pseudomonas Aeruginosa
Interventions
MEDI3902, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Englewood, Colorado • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 3 Interventional

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

NCT00578695
View directory record Official record
Conditions
Hyponatremia
Interventions
lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Bakersfield, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Jul 25, 2026, 8:20 AM EDT
Not listed Phase 1 Interventional

IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma

NCT00003842
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
Biological · Drug · Procedure
Lead sponsor
Barrett Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 25, 2026, 8:20 AM EDT
Terminated No phase listed Observational Results available

ST Segment Detection Study

NCT00930969
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ICD
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
17
States / cities
Anchorage, Alaska • Brandon, Florida • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

NCT02963766
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jul 25, 2026, 8:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation

NCT03047629
View directory record Official record
Conditions
Parkinson's Disease, Constipation
Interventions
ENT-01, Placebo
Drug · Other
Lead sponsor
Enterin Inc.
Industry
Eligibility
30 Years to 86 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jul 25, 2026, 8:20 AM EDT
Recruiting Phase 2 Interventional

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cemiplimab, Platinum-based chemotherapy, REGN7075
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
15
States / cities
Orange, California • Skokie, Illinois • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 25, 2026, 8:20 AM EDT